FA11s1.i
Merge
PascalFrancis
Racine
Merge
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Merge (PascalFrancis)

Index « FA11s1.i » - entrée « RASCOL (O.) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
RASCOL (A.) < RASCOL (O.) < RASCOL (Oliver)  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000355 (2001) O. Rascol ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A. M. Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J. L. Montastruc ; Y. AgidIdazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
003246 (1994) O. Rascol ; N. Fabre ; O. Blin ; J. Poulik ; U. Sabatini ; J.-M. Senard ; M. Ane ; J.-L. Montastruc ; A. RascolNaltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
003308 (1995) O. Rascol ; U. Sabatini ; N. Fabre ; J. M. Senard ; M. Simonetta-Moreau ; J. L. Montrastruc ; M. Clanet ; A. RascolAbnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
003322 (1995) J.-L. Montastruc ; N. Fabre ; O. Blin ; J.-M. Senard ; O. Rascol ; A. RascolDoes fluoxetine aggravate Parkinson's disease ? A pilot prospective study
003561 (1997) N. Andreu ; C. Damase-Michel ; J.-M. Senard ; O. Rascol ; J.-L. MontastrucA dose-ranging study of selegiline in patients with Parkinson's disease : Effect on platelet monoamine oxidase activity
003730 (1998) O. Rascol ; D. J. Brooks ; E. R. Brunt ; A. D. Korczyn ; W. H. Poewe ; F. StocchiRopinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study
003731 (1998) A. D. Korczyn ; D. J. Brooks ; E. R. Brunt ; W. H. Poewe ; O. Rascol ; F. StocchiRopinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study
003855 (1998) O. Rascol ; K. Sieradzan ; H. Peyro-Saint-Paul ; C. Thalamas ; C. Brefel-Courbon ; J. M. Senard ; P. Ladure ; J. L. Montastruc ; A. LeesEfaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
003856 (1998) N. Fabre ; C. Brefel ; U. Sabatini ; P. Celsis ; J. L. Montastruc ; F. Chollet ; O. RascolNormal frontal perfusion in patients with frozen gait
003995 (1999) J.-L. Montastruc ; M. Ziegler ; O. Rascol ; M. MalbezinA randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
003A59 (1999) J. L. Montastruc ; O. Rascol ; J.-M. SenardTreatment of Parkinson's disease should begin with a dopamine agonist
003A99 (1999) O. RascolL-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA11s1.i -k "RASCOL (O.)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Merge/FA11s1.i  \
                -Sk "RASCOL (O.)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Merge/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Merge
   |type=    indexItem
   |index=    FA11s1.i
   |clé=    RASCOL (O.)
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024